A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

  • Cancer
  • Breast Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Adana
  • Alkmaar
  • Almada
  • Ankara
  • Arkhangelsk
  • Arnhem
  • Athens
  • Atlanta
  • Bad Nauheim
  • Banja Luka
  • Barakaldo
  • Barcelona
  • Beaverton
  • Beograd
  • Berlin
  • Bernards
  • Białystok
  • Bogotá
  • Boston
  • București
  • Busan
  • Bydgoszcz
  • Catania
  • Cercado de Lima
  • Chang Wat Chiang Mai
  • chang-chun-shi
  • cheongju
  • Chihuahua
  • Ciudad de México
  • Clermont-Ferrand
  • Cluj-Napoca
  • Commack
  • Craiova
  • Dijon
  • Edirne
  • Edmonton
  • Essen
  • Florence
  • Gdańsk
  • Genoa
  • Goyang-si
  • Graz
  • Grosseto
  • Guilherand-Granges
  • Hackensack
  • Hamburg
  • hang-zhou-shi
  • Harrisburg
  • Harrison
  • Harvey
  • Heidelberg
  • Hlavní město Praha
  • Hradec Králové
  • Iași
  • Innsbruck
  • İstanbul
  • Ivanovo Oblast
  • İzmir
  • Kazan
  • Kitchener
  • Konin
  • Kraków
  • Krung Thep Maha Nakhon
  • Kuopio
  • La Roche-sur-Yon
  • Limoges
  • Linköping
  • Linz
  • Lisboa
  • Liverpool
  • Lombardia
  • Lublin
  • Macquarie University
  • Madrid
  • Majadahonda
  • Marietta
  • moche
  • Monterrey
  • Montería
  • Montpellier
  • Montréal
  • Murdoch
  • México
  • München
  • nan-jing-shi
  • Napoli
  • New York
  • Olomouc
  • orenburg
  • Ottawa
  • Paris
  • Pierre-Bénite
  • Plovdiv
  • Pontedera
  • Porto
  • Québec
  • Reggio Emilia
  • Rio
  • Rockville
  • San Borja
  • San Cristóbal de La Laguna
  • Santiago de Compostela
  • Sarajevo
  • Seoul
  • shang-hai-shi
  • Sofia
  • South Brisbane
  • St Albans
  • St. Louis
  • stepanovskoye
  • Stockholm
  • Strasbourg
  • Surquillo
  • Szczecin
  • Taipei City
  • Thessaloniki
  • Toronto
  • Trier
  • Tucson
  • Turku
  • Udine
  • Ulsan
  • Uniondale
  • Uppsala län
  • València
  • Vancouver
  • Vandœuvre-lès-Nancy
  • Varna
  • Venezia
  • Waratah
  • Warszawa
  • Wien
  • Wrocław
  • Zaragoza
  • Łódź
  • София
Trial Identifier:

NCT02340221 2014-003185-25 GO29058

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy. There will be a 2:1 randomization to the taselisib arm versus the placebo arm. Enrollment will be enriched for participants with PIK3CA mutant tumors via central testing. The anticipated duration of the study is approximately 3.5 years.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT02340221,GO29058,2014-003185-25 Trial Identifier
      Taselisib, Placebo, Fulvestrant Treatments
      Breast Cancer Condition
      Official Title

      A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

      Eligibility Criteria

      Female Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Postmenopausal women with histologically or cytologically confirmed locally advanced or metastatic estrogen receptor (ER) positive breast cancer
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Participants for whom endocrine therapy (example [e.g.], fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study
      • Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer
      • Radiologic/objective evidence of breast cancer recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor (AI), or progression while on or within 1 month of the end of prior AI treatment for locally advanced or metastatic breast cancer
      • Measurable disease via Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) or non-measurable, evaluable disease with at least one evaluable bone lesion via RECIST v1.1
      • Consent to provide a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or a minimum of 20 (25 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue for oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutation testing
      • A valid cobas PIK3CA mutation result by central testing is required
      • Adequate hematologic and end-organ function within 28 days prior to treatment initiation
      Exclusion Criteria
      • Human epidermal growth factor receptor 2 (HER2)-positive disease by local laboratory testing (immunohistochemistry 3 positive [IHC 3+] staining or in situ hybridization positive)
      • Prior treatment with fulvestrant
      • Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, mammalian target of rapamycin (mTOR) inhibitor (e.g. everolimus), or protein kinase B (AKT) inhibitor
      • Prior anti-cancer therapy within 2 weeks prior to Day 1 of Cycle 1
      • Prior radiation therapy within 2 weeks prior to Day 1 of Cycle 1
      • All acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the Investigator
      • Prior treatment with greater than (>) 1 cytotoxic chemotherapy regimen for metastatic breast cancer
      • Concurrent hormone replacement therapy
      • Known untreated or active central nervous system (CNS) metastases
      • Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications
      • History of inflammatory bowel disease or active bowel inflammation
      • Clinically significant cardiac or pulmonary dysfunction
      • Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B or C virus

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now